AstraZeneca PLC spinout Viela Bio Inc. filed for an IPO of up to $150 million.
Cambridge, U.K.-based AstraZeneca said in February 2018 that its research and development unit, MedImmune LLC, would move out six experimental compounds from its early-stage inflammation and autoimmunity programs to form Viela Bio, an independent biotech company.